Number of pages: 100 | Report Format: PDF | Published date: 08 September, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global hospital acquired disease testing market was pegged at ~US$ 3.67 billion in 2021 and is expected to witness a CAGR of ~7.7% during the forecast period.
Nosocomial infection, also known as hospital acquired disease, is a localised or systemic ailment in patients that develops as a result of an adverse reaction to infectious toxin agents while receiving medical care and were not present at the time of admission. Longer hospital stays, antimicrobial resistance, permanent disabilities, and a higher mortality rate are all implications of hospital acquired infections. Viruses, fungus parasites, and bacteria all serve as pathogens that cause illnesses that patients contract while hospitalised. Moreover, Infections at surgical wound, pneumonia linked to ventilators, and urinary tract infections linked to catheters are among illnesses acquired in hospitals. Microarray, PCR, and solid phase hybridization are the methods utilised for disease testing, diagnosis, and prevention that are associated with hospital acquired conditions.
The prevalence of pathogens, bacterial, fungal, and viral diseases, as well as rising morbidity rates from infections around the globe, are some of the key factors influencing the global market for hospital acquired diseases testing. Another significant factor is the lengthening hospital stays, which are mostly brought on by hospital acquired infections. Furthermore, the intensive care units (ICU) and emergency rooms have a higher risk of HAI (ER). According to CDC estimates, 5% of hospitalised patients contract a HAI in some form within 72 hours of their admission. Excluded from consideration are infections that are still developing but are not yet clinically evident.
The global hospital acquired disease testing market has been analyzed into fix perspectives by product, test type, application, infection type, end user and region.
Hospital Acquired Disease Testing Market by Product
Based on product, the global hospital acquired disease testing market has been segmented into Instruments, Reagents and Consumables. The reagents segment dominated the market during forecast period owing to low awareness and a high prevalence of hospital acquired illnesses in low- and middle-income nations are attributed for the segment's growth.
Hospital Acquired Disease Testing Market by Test Type
Based on test type, the global hospital acquired disease testing market has been segmented into molecular diagnostics, immunoassay and others. During forecast period, the immunoassay segment dominated the global hospital acquired disease testing market. The increase in cancer cases, infectious disorders, and sudden pandemic outbreaks are all factors contributing to the segment's growth.
Hospital Acquired Disease Testing Market by Application
Based on application, the global hospital acquired disease testing market has been segmented into disease testing, drug-resistance testing. The drug resistance testing segment dominated the global hospital acquired disease testing market during forecast period.
Hospital Acquired Disease Testing Market by Infection Type
Based on infection type, the global hospital acquired disease testing market has been segmented into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI). The urinary tract infections (UTI) showed the highest growth during the projected period owing to which the market opportunity for infection diagnostics acquired in hospitals can be credited. Since pneumonia is a common diagnosis among hospitalised patients.
Hospital Acquired Disease Testing Market by End User
Based on end user, the global hospital acquired disease testing market has been segmented into hospital, standalone laboratories, and others. The hospital segment dominated during forecast period owing to the rapid rise of patients and pandemic outbreak.
Hospital Acquired Disease Testing Market by Region
Based on region, the global hospital acquired disease testing market has been segmented into North America, Europe, Asia Pacific and Rest of the World. North America is expected to continue to dominate during the projected period and have the greatest revenue share in the global market. This is due to an ageing population, stringent regulatory standards, an improved healthcare infrastructure, a rise in hospital stays, and a rising risk of getting an infection acquired in a hospital.
The market in the Asia Pacific is anticipated to develop at the fastest rate during the forecast period due to the region's laxer regulations, rising demand for cutting-edge drugs and treatments, and rising medical tourism.
Some of the prominent market players in the global hospital acquired disease testing market include